Results 51 to 60 of about 97,775 (211)

Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: Potential clinical value [PDF]

, 2002
Anti-Saccharomyces cerevisiae antibodies (ASCA) have been described as specific markers in Crohn's disease and their healthy first-degree relatives. 171 patients with Crohn's disease, their 105 first-degree relatives, 145 patients with ulcerative colitis
Folwaczny, Christian, Glas, J., Herbinger, K. H., Hoelscher, Michael, Török, H.-P., Vilsmaier, F.   +5 more
core   +1 more source

The microbiome of Crohn’s disease aphthous ulcers

Gut Pathogens, 2018
Background Reduced intestinal microbial diversity and bacterial imbalance (dysbiosis) are seen in studies of Crohn’s disease. As it is difficult to obtain biopsy samples before disease presentation, the earliest mucosal lesions in Crohn’s disease ...
Claire L. O’Brien, Christopher J. Kiely, Paul Pavli   +2 more
doaj   +1 more source

Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report

SAGE Open Medical Case Reports, 2023
Alopecia areata is a non-scarring, autoimmune hair loss disorder that is associated with inflammatory bowel disease. Alopecia areata and inflammatory bowel disease may have a common pathogenic mechanism that involves the Janus kinase/STAT pathway.
Leah A Johnston, Cathy Lu, Susan M Poelman   +2 more
doaj   +1 more source

The Effects of Acupuncture on Crohn’s Disease: a systematic review and meta-analysis

Journal of Pharmacopuncture, 2023
Objectives: Crohn’s disease is a chronic gastrointestinal disease that belongs to inflammatory bowel disease. This systematic review aims to assess the level of evidence in randomized controlled trials (RCTs) on the effects of acupuncture for Crohn’s ...
Joon Hyun Bae, Seo Young Kang, Si Eun You, Hye In Jeong, Soobin Jang, Kyeong Han Kim   +5 more
doaj   +1 more source

Additional file 4: of Genome analysis of E. coli isolated from Crohnâ s disease patients

, 2017
(A) Mauve alignment of CD-E. coli isolates from one patient (alignment made for RCE01, RCE02, RCE03, RCE03 and RCE06). (B) Heatmap of the phylogenetic distance between E. coli strains. Distances between strains are calculated as the median distance of core genes (see Methods). Phylogroups of E. coli are designated (A, B1, E, B2, D, F).
Rakitina, Daria, Manolov, Alexander, Kanygina, Alexandra, Garushyants, Sofya, Baikova, Julia, Alexeev, Dmitry, Ladygina, Valentina, Kostryukova, Elena, Larin, Andrei, Semashko, Tatiana, Karpova, Irina, Babenko, Vladislav, Ruzilya Ismagilova, Malanin, Sergei, Gelfand, Mikhail, Ilina, Elena, Gorodnichev, Roman, Lisitsyna, Eugenia, Aleshkin, Gennady, Scherbakov, Petr, Khalif, Igor, Shapina, Marina, Maev, Igor, Andreev, Dmitry, Govorun, Vadim   +24 more
openaire   +1 more source

Crohn's disease activity index and Vienna classification - Is it worthwhile to calculate before surgery? [PDF]

, 2006
Background: Crohn's disease (CD) patients with increased disease activity may reveal an increased risk for perioperative complications. The `Crohn's disease activity index' (CDAI) and the `Vienna classification' (VC) were developed for standardized ...
A. Beham, Best WR, Best WR, Dirks E, Friedman S, Goebell H, Greenstein AJ, H.J. Schlitt, Heimann TM, K.W. Jauch, Kiran RP, Lichtenstein GR, M. Rentsch, Mekhjian HS, Michelassi F, Murch SH, Otterson MF, Post S, Post S, Post S, Raab Y, Scholmerich J, Shepherd HA, Speranza V, Veloso FT, Wettergren A, Whelan G, Yamamoto T, Yamamoto T, Yamamoto T   +29 more
core   +1 more source

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

BMC Gastroenterology, 2022
Background and aims There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients. Methods We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in ...
Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jørgen Jahnsen, Charles Lees, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong-Hyeon Kim, Sung Jeong Lee, Raja Atreya   +15 more
doaj   +1 more source

WHAT DO DENTISTS NEED TO KNOW ABOUT CROHN’S DISEASE?

Revista Naval de Odontologia On Line, 2021
Crohn’s disease is described as a complex inflammatory bowel disease, characterized by transmural lesions and inflammation that can affect the entire gastrointestinal tract.
Fernando Gabriel de Araújo Chagas, Anna Thereza Thomé Leão, Sandra Regina Torres   +2 more
doaj   +1 more source

Additional file 11: of Genome analysis of E. coli isolated from Crohnâ s disease patients

, 2017
Bacteriocin production test in CD-associated strains. (DOC 42Â kb)
Rakitina, Daria, Manolov, Alexander, Kanygina, Alexandra, Garushyants, Sofya, Baikova, Julia, Alexeev, Dmitry, Ladygina, Valentina, Kostryukova, Elena, Larin, Andrei, Semashko, Tatiana, Karpova, Irina, Babenko, Vladislav, Ruzilya Ismagilova, Malanin, Sergei, Gelfand, Mikhail, Ilina, Elena, Gorodnichev, Roman, Lisitsyna, Eugenia, Aleshkin, Gennady, Scherbakov, Petr, Khalif, Igor, Shapina, Marina, Maev, Igor, Andreev, Dmitry, Govorun, Vadim   +24 more
openaire   +1 more source

Asymptomatic Crohn’s disease identified in a patient being treated with secukinumab: A case report

SAGE Open Medical Case Reports, 2019
IL-17 antagonism is among the most potent treatments for psoriasis. Generally safe, new onset and exacerbations of inflammatory bowel disease may occur in association with IL-17 therapy.
Wasim Haidari, Sarah Al-Naqshabandi, Christine S Ahn, Richard S Bloomfeld, Steven R Feldman   +4 more
doaj   +1 more source